The cancer registry as an ally in monitoring treatment effectiveness

Por F.A. Costa, C. Ramos, R. Murteira, T. Almodovar, J.L. Passos-Coelho, M.I. Carvalho, L. Costa, M.J. Brito, S. Ramos, M. Ferreira, A.C. Miranda
Publicado em 2019-01-01

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Por R.E. Coleman, M. Collinson, W. Gregory, H. Marshall, R. Bell, D. Dodwell, M. Keane, M. Gil, P. Barrett-Lee, D. Ritchie, A. Bowman, V. Liversedge, R.H. De Boer, J.L. Passos-Coelho, S. O'Reilly, G. Bertelli, J. Joffe, J.E. Brown, C. Wilson, J.C. Tercero, J. Jean-Mairet, R. Gomis, D. Cameron
Publicado em 2018-11-01